{Reference Type}: Journal Article
{Title}: Update MRONJ and perspectives of its treatment.
{Author}: Voss PJ;Poxleitner P;Schmelzeisen R;Stricker A;Semper-Hogg W;
{Journal}: J Stomatol Oral Maxillofac Surg
{Volume}: 118
{Issue}: 4
{Year}: Sep 2017
{Factor}: 2.48
{DOI}: 10.1016/j.jormas.2017.06.012
{Abstract}: Antiresorptive agents are widely used in catabolic bone diseases. Not only bisphosphonates but also new drugs like Denosumab may induce osteonecrosis of the jaw as a side effect. The present review describes the current effect mechanisms of commonly used antiresorptives, pathogenetic theories for the development of antiresorptive-related osteonecrosis of the jaw (ARONJ), and potential risk factors. Furthermore, diagnostic modalities and treatment options as well as new and innovative strategies are discussed. The major key factor to avoid the occurrence of ARONJ still remains the implementation of throughout preventive measures.